Form 8-K Moderna, Inc. For: Feb 23

Go back to Form 8-K Moderna, Inc. For: Feb 23

Moderna (MRNA) PT Lowered to $185 at Morgan Stanley Following EPS

February 23, 2023 12:39 PM EST

Morgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA) to $185.00 (from $205.00) while maintaining a Overweight rating following earnings.

The analyst commented, "4Q22 was generally in-line. 2023 COGS of 35-40% was above expectations and the most notable downside driver in our... More